{"anticipatedPostingDate":"2027-05","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"From Cycle 1 Day 1 up to 30 days after the last study treatment or day prior to start of subsequent antimyeloma therapy (up to 7.1 years)","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","type":"SECONDARY"}